Bausch + Lomb Co. (NYSE:BLCO - Free Report) - Investment analysts at HC Wainwright upped their Q2 2024 earnings estimates for Bausch + Lomb in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst Y. Chen now forecasts that the company will earn $0.20 per share for the quarter, up from their previous forecast of $0.17. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Bausch + Lomb's current full-year earnings is $0.65 per share. HC Wainwright also issued estimates for Bausch + Lomb's Q3 2024 earnings at $0.26 EPS, FY2024 earnings at $0.89 EPS, Q1 2025 earnings at $0.24 EPS, Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.25 EPS and Q4 2025 earnings at $0.29 EPS.
A number of other equities analysts also recently issued reports on BLCO. Evercore cut their price target on Bausch + Lomb from $17.00 to $15.00 and set an "in-line" rating for the company in a research note on Thursday. Barclays upped their price target on Bausch + Lomb from $17.00 to $18.00 and gave the stock an "equal weight" rating in a report on Monday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Bausch + Lomb in a research note on Wednesday. Wells Fargo & Company upped their target price on shares of Bausch + Lomb from $21.00 to $23.00 and gave the stock an "overweight" rating in a research note on Thursday, February 22nd. Finally, Royal Bank of Canada dropped their price target on shares of Bausch + Lomb from $20.00 to $18.00 and set an "outperform" rating on the stock in a research report on Monday, April 22nd. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $19.27.
Read Our Latest Stock Analysis on Bausch + Lomb
Bausch + Lomb Stock Down 1.9 %
Shares of NYSE:BLCO traded down $0.26 during midday trading on Friday, hitting $13.60. 533,372 shares of the company's stock were exchanged, compared to its average volume of 490,739. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.74 and a quick ratio of 1.09. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.95. The company has a market cap of $4.78 billion, a PE ratio of -14.49, a price-to-earnings-growth ratio of 1.33 and a beta of 0.47. The stock has a 50 day moving average price of $15.84 and a 200-day moving average price of $15.63.
Bausch + Lomb (NYSE:BLCO - Get Free Report) last released its quarterly earnings data on Wednesday, May 1st. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.02). The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.06 billion. Bausch + Lomb had a negative net margin of 7.81% and a positive return on equity of 3.57%. The company's revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 EPS.
Institutional Trading of Bausch + Lomb
Several hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd bought a new position in shares of Bausch + Lomb in the 3rd quarter worth $466,000. River Road Asset Management LLC grew its position in Bausch + Lomb by 21.6% during the fourth quarter. River Road Asset Management LLC now owns 1,938,207 shares of the company's stock valued at $33,066,000 after acquiring an additional 343,772 shares during the last quarter. Black Swift Group LLC purchased a new position in shares of Bausch + Lomb during the third quarter worth approximately $170,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Bausch + Lomb in the 3rd quarter worth approximately $5,091,000. Finally, TD Asset Management Inc purchased a new position in Bausch + Lomb in the 3rd quarter worth $2,752,000. 11.07% of the stock is currently owned by institutional investors.
Bausch + Lomb Company Profile
(
Get Free Report)
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.
Further Reading
Before you consider Bausch + Lomb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch + Lomb wasn't on the list.
While Bausch + Lomb currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
